RIST-rPB-2015

Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma

Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma

Recruiting

Summary

Children, adolescents and young adults with relapsed or treatment refractory pineoblastoma (rPB) represent a group of patients with dismal prognosis for whom a recommended standard salvage therapy is currently not available.

The multimodal metronomic approach, which combines molecularly targeted drugs (rapamycin and dasatinib) with conventional chemotherapy (irinotecan and temozolomide), is being randomly investigated as a new treatment strategy for patients with rPB. The aim is to evaluate the therapeutic benefits of molecular agents for the treatment of rPB.

Main inclusion criteria

  • Patients with relapsed and refractory high-grade pineoblastome (rPB)
  • Children, adolescents and young adults (0 - 25 years)

Sponsor

University of Regensburg

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzinformationen